INVESTORS.

Regulus aims to develop novel oligonucleotide therapeutics that are designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases.

Home Page Ticker
NASDAQRGLS
Press Releases.
November 26, 2024
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today...

November 07, 2024
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates

Completed enrollment in the fourth cohort of the Phase 1b multiple-ascending dose (MAD) clinical trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disease (ADPKD)...

October 08, 2024
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today...

More press releases

Events.
Piper Sandler 36th Annual Healthcare Conference
Wednesday, December 4, 2024
11:10am EST
Evercore 7th Annual HealthCONx Conference
Tuesday, December 3, 2024
3:50pm EST
Jones Virtual Genetic Medicines Day
Monday, November 25, 2024
2:00pm EST

Listen to the Webcast

More events

upcoming event.
No events to display

more events

Corporate Presentation

Download

email alerts.

Sign up for email alerts to receive the latest financial information from Regulus Therapeutics Inc.

Sign Up

IR contact.

Phone: 858-202-6300
Email: ir@regulusrx.com

Contact Us